Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-2870 plus pembrolizumab versus standard neoadjuvant chemotherapy plus pembrolizumab in high-risk early-stage TNBC or HR-low/HER2-negative breast cancer
jRCT2031250231Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of sacituzumab tirumotecan and pembrolizumab in triple-negative breast cancer (TNBC) and breast cancer (2 arms), sponsored by Merck & Co. Primary endpoints: Pathologic complete response rate and Event-free survival. Started Sep 2025; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecanpembrolizumab
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on jRCT2031250231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250231.